Search 

If you’ve been looking for something different from your CRO, choose the one that stands out.

Welcome to Clinilabs, where science leads business.

Clinilabs is a premier full-service CRO that specializes in applying scientific principles to phase I, II, and III studies in order to bring investigational products to the threshold of successful approval.  Our unique development strategy builds value into early phase development programs, carrying promising products forward swiftly and abandoning failures early.  We enable our clients to apply their resources wisely and maximize the value of their drug and device portfolios.
 
Expect something different from your CRO – Science. Communication. Collaboration. Results. 

ClinSmart is known as a trusted partner for both simple and comprehensive development programs required by biopharmaceutical and medical device companies, since 1994. Our academically and industry trained staff, combined and supported by the latest proven technologies, focuses on improving the efficiency of clinical development while minimizing risk and costs. We guarantee upfront strategic clinical planning, high quality regulatory packages including risk mitigation strategies prior to the start of any project, organizational structure which results in lower costs than a large CRO, global capabilities, and overall clinical and scientific expertise. Our experienced staff will work closely with your team to understand the requirements of your development program and will ensure that the right team is put into place to accomplish the tasks at hand.

For more information about our team and services, please visit our website (www.clinsmart.com) and LinkedIn page.

Present in 146 countries, CCEs form an active network of over 4,000 members at the service of French companies around the world.

Selected for their competence and their international experience, the 'Conseillers du Commerce extérieur de la France' (CCE - French Foreign Trade Advisor) are appointed for three years through a prime ministerial decree, on the recommendations of the Minister for Foreign Trade. For more than 115 years, on a voluntary basis, they have been placing their experience at the service of France's economic presence around the world.

Colliers International Group Inc. (NASDAQ: CIGI; TSX: CIG) is a global leader in commercial real estate services with more than 16,300 professionals operating from 502 offices in 67 countries. With an enterprising culture and significant insider ownership, Colliers professionals provide a full range of services to real estate occupiers, owners and investors worldwide across a broad range of property types, including:

• Brokerage;
• Global corporate solutions;
• Investment sales and capital markets;
• Project management and workplace solutions;
• Property and asset management;
• Consulting, valuation and appraisal services; and,
• Customized research and thought leadership. 

Colliers International has been ranked among the top 100 outsourcing firms by the International Association of Outsourcing Professionals' Global Outsourcing for 10 consecutive years, more than any other real estate services firm.

Inflammation is the mammalian response to infection. Normally it is defensive and thwarts pathogenic assaults but occasionally it runs amok, leading to physiological chaos and death. We are interested in the regulation of the inflammatory pathway as mediated by various cytokines. We focus on the regulation of interleukin-1 by the interleukin-1 receptor antagonist, determine its interactions with other cytokines and assay the cellular and molecular consequences when interleukin expression is altered. Transgenic mice and mice deleted for genes encoding these regulatory molecules have been generated and we utilize them as tools for deciphering these inflammatory pathways.

Cells use receptor mediated endocytosis to take up proteins from their environment, be it for antigen processing, polypeptide hormone signaling, nutrient supplementation, growth factor stimulation or receptor modulation. We are studying the endocytic pathway and receptor recycling using a molecular genetic analysis in the model organism, C. elegans. Our purpose is to identify new key molecular components in the pathway and to elucidate their structures and functions.

Mathew S. Maurer, MD, is medical director of The HCM Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. A general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation, he has received grants from the National Institute on Aging to study cardiovascular changes in older patients and specializes in the care of patients with heart failure and a preserved ejection fraction, including patients with HCM. Dr. Maurer is an associate professor of Medicine at Columbia University, College of Physicians and Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYork-Presbyterian Hospital. Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork-Presbyterian/Columbia.

Innovation | Value Creation | Top-Bottom Line Growth | Operation Efficiencies | Transformation | Strategic Growth Partners I High Performing Organizations

Accomplished leader drives results for corporate divisions ($200MM to $2BB). Exceeds target goals with focused and differentiated strategy, consumer insight-driven growth plans, operational excellence and building accountable, empowered organizations.

CREATES STRATEGIC VALUE

Relentless focus on articulating and driving clear strategic advantages within the organization: brand value proposition, customer value, cost structure. Connects with consumers/customers to understand their needs, then uses this insight to continually strengthen business strategy. The result is acceleration of top and bottom line growth, category leadership and market share.

ACHIEVES OPERATIONAL EFFICIENCIES

Works across the entire value chain to quickly assess and prioritize where resources must be refocused and process improvements must be made to improve operating margins and lower capital investment needs. Applies Six Sigma principles to eliminate redundancies and potential points of confusion so that the business and brands can remain proactive in creating value and maintaining their category leadership positions.

CHAMPIONS INNOVATION

Reaches beyond “business as usual” to create products and brand value positions that standout in the market and resonate with consumers. Continually leverages consumer insights to ensure disciplined innovation so that brands stay relevant and meaningful with consumer needs.

TRANSFORMS ORGANIZATIONS

Advocates continuous professional development of people within organizations to create a break-through culture. This results in highly engaged work teams where ownership and risk-taking are encouraged; streamlined organization structures and decision processes. As a result the organization is more nimble and can quickly meet the changing needs of today’s dynamic and multi-cultural consumer market.

Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.

Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.  
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.  
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!

----

Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis. 
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business. 
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients ! 

CreaPharm group is a customer-focused team of 164 people applying their expertise and innovative solutions to offer a first-class service to their 250 active customers.

We are a mid-size subcontractor that is big enough to offer high range of services of the highest quality while at the same time being small enough to offer dedicated care and to adapt its processes according to the specificities of each client request.

Our 4 facilities are fully compliant with Good Manufacturing Practices and Good Distribution Practices and are inspected by the French medicines agency ANSM for human medicinal products and the ANSES for veterinary products.

Clinical Supplies:

·         GMP manufacturing,

·         Packaging and labelling,

·         International distribution,

·         Comparator and ancillary goods sourcing,

·         IMP importation and QP release services,

·         Biological sampling kit production

Pharmaceutical Contract Manufacturing:

·         Packaging design and development, Packaging of market drugs,

·         Special packing and repacking activities,

·         Late stage customization

Cosmetic Contract Manufacturing:

·         Formulation of cosmetic products,

·         A wide range of formulas available,

·         Packaging design and development, Manufacturing & packaging of cosmetic products